Female pattern hair loss (FPHL) presents with diffuse thinning over the mid-frontal scalp, for which various treatment modalities have been tried. Although currently, oral 5 a-reductase inhibitors such as finasteride are being used, their clinical efficacy remains controversial. We retrospectively investigated 544 premenopausal or postmenopausal patients with FPHL who were prescribed finasteride at a dose of 2.5 mg/day. Our study excluded patients with a follow-up period of < 3 months and patients who were prescribed other FPHL treatment modalities including topical minoxidil. Finally, 112 patients were evaluated based on their medical records and clinical photographs. Based on assessment using the Ludwig scale at the time of their initial visit, among 112 patients studied, 59 patients were classified as belonging to grade I, 47 were grade II, and 6 were grade III. Using global photographs, we found that 33 (29.5%) of the 112 patients studied showed slight improvement, 73 (65.2%) showed significant improvement, whereas no change was recorded in 6 (5.4%). We could demonstrate efficacy of administration of finasteride at a dose of 2.5 mg/day for patients with FPHL and also found that finasteride has a better effect on hair growth when patients had a lower Ludwig score and an older age at onset K E Y W O R D S androgenetic alopecia, female pattern hair loss, finasteride
| I NTR OD U CTI ON
Pattern hair loss is the most common cause of hair loss in both men and women. Pattern hair loss in women (female pattern hair loss [FPHL] ), which presents with diffuse thinning over the central portion of the scalp, spares the frontal hairline and is characterized by a wider midline part of the crown than on the occipital scalp (Shapiro, 2007) . In approximately 50% of women, FPHL can develop at any time during their lifetime after the onset of puberty and the prevalence increases with age (Boersma et al., 2014; Price, 2003) .
Various treatment strategies including use of topical minoxidil, oral anti-androgen agents, and 5-areductase inhibitors including finasteride and dutasteride have been tried as treatment for FPHL (Blumeyer et al., 2011) . However, the only treatment for FPHL approved by the U.S. Food and Drug Administration is use of topical minoxidil.
Finasteride is a competitive and specific inhibitor of type II 5a-reductase and prevents the conversion of testosterone to dihydrotestosterone (DHT), the latter known to play a role in causing hair follicle miniaturization (Levy & Emer, 2013) . Large-scale studies have proved that intake of 1 mg/day of finasteride reduces hair loss, and additionally increases the total and anagen hair count in men with male pattern hair loss (Kaufman et al., 1998; Leyden et al., 1999) . Therefore, administration of oral finasteride at a dose of 1 mg/day is recommended to improve and/or prevent progression of androgenetic alopecia (AGA) in male patients (Blumeyer et al., 2011) . However, clinical efficacy of finasteride use in FPHL remains controversial. A large-scale, multicenter, randomized, placebo-controlled trial investigating the effects of daily administration of 1 mg of finasteride in women showed no significant effect on hair growth (Price et al., 2000) . However, case reports have shown that administration of finasteride at a dose of 5 mg/day for women led to a significant change in mean hair density and thickness but was associated with several adverse effects (Kohler, Tschumi, Bodmer, Schneiter, & Birkhaeuser, 2007; Oliveira-Soares, E Silva, Correia, & Andr e, 2013; Yeon et al., 2011) .
Although a study has demonstrated the beneficial effects of finasteride at a dose of 2.5 mg/day, the number of patients studied was small, and the study included only premenopausal women (Iorizzo, Vincenzi, Voudouris, Piraccini, & Tosti, 2006) . Therefore, we retrospectively reviewed charts for post and premenopausal women (those who did not plan to get pregnant) to investigate the clinical efficacy and safety of daily administration of 2.5 mg of finasteride in this population.
| P AT IE N TS A N D M E TH ODS

| Patient population
We retrospectively investigated 544 patients with FPHL who presented to our clinic between January 2012 and April 2016 and had been prescribed finasteride 2.5 mg/day. All of the patients were either postmenopausal women or premenopausal women without a plan to get pregnant. Other inclusion criteria were normal androgen, iron, and ferritin levels, as well as normal thyroid function test results. We excluded patients with a follow-up period of < 3 months, patients who were prescribed other FPHL treatment modalities including topical minoxidil, oral anti-androgens, and those diagnosed with any systemic illness within the previous 6 months. Finally, 112 patients were included and evaluated based on their medical records and clinical photographs.
| Efficacy assessment
Global photographs were taken using a digital camera (Canon EOS 70D). We took pictures at the time of the patient's first visit and subsequently at every 3-month follow-up visit. Two expert panels of dermatologists compared pictures obtained at the time of their first visit with those obtained at the time of their last follow-up. A 3-point scale was used to grade the change in scalp hair appearance as follows: no response or aggravation (0), slightly improved (1), and significantly improved (2).
| Statistical analysis
Data were expressed as means 6 SDs. Statistical analysis was performed using the SPSS statistical package (SPSS® 20.0 for Windows; SPSS Inc., Chicago, IL). Spearman's Rho correlation test was used to evaluate the relationship between improvement of scalp hair appearance and patient characteristics including age, age at the time of onset of this condition, duration of FPHL, and Ludwig grade. The level of statistical significance was set at p 5 .05.
| R ESU L TS
| Baseline characteristics
The patients' mean age at initial visit was 54.1 6 7.5 years (range, 30-73 years). Mean age of onset was 40.7 6 10.8 years (range, 17-61 years), mean follow-up duration was 17.6 6 12.9 months (range, 3-59 months), and mean duration of FPHL was 13.4 6 9.5 years (range, 1-41 years).
| Global photographs assessment
Results of baseline characteristics and improvement in scalp hair appearance are shown in Table 1 . Among the 112 patients studied, 33 (29.5%) showed slight improvement, 73 (65.2%) showed significant improvement, whereas no change was recorded in 6 (5.4%) (Figure 1 
| Safety
No patient reported adverse effects such as headache, menstrual irregularity, and/or dizziness.
| DI SCUS SION
FPHL is the most common cause of alopecia in women and differs from male pattern baldness in terms of epidemiology, clinical presentation, and management (Sinclair et al., 2011) . The pathogenesis of FPHL
has not yet been completely understood. Although androgens are considered to play a role in women who demonstrate features of hypergonadism, most women with FPHL have normal androgen levels (Schmidt, Lindmaier, Trenz, Schurz, & Spona, 1991) . Additionally, the fact that patients demonstrate varied responses to various treatment modalities suggests that FPHL is a condition that arises from an interplay of multiple pathogenetic mechanisms.
Several medications including topical minoxidil, oral finasteride, and oral anti-androgens are widely used to treat FPHL. The U.S. Food and Drug Administration has approved 2% topical minoxidil use for the treatment of FPHL. Usually, anti-androgens including spironolactone, and cyproterone acetate have been used in women with FPHL with concomitant signs of androgen excess (Olsen et al., 2005; Sinclair & Dawber, 2001) . Finasteride is a competitive and specific inhibitor of type II 5 a-reductase and prevents the conversion of testosterone into dihydrotestosterone (DHT), the latter known to play a role in causing hair follicle miniaturization (Levy & Emer, 2013) .
Several reports pertaining to treatment of FPHL using oral finasteride have shown variable efficacy (Boersma et al., 2014; Boychenko, Bernstein, & Schweiger, 2012; Carmina & Lobo, 2003; Hong, Chiu, Chan, Chen, & Lin, 2007; Iorizzo et al., 2006; Kohler et al., 2007; Kim, Song, Ko, Kim, & Kim, 2012; Oliveira-Soares et al., 2013; Price, 2003; Shum, Cullen, & Messenger, 2002; Thai & Sinclair, 2002; Tr€ ueb, 2004;  Whiting , reported by Yeon et al. (2011) , patients with a higher Ludwig grade had better effects of finasteride on hair growth. Maybe, this is due to a somewhat lesser quantity of Ludwig III patients studied in our study.
Limitations of our study are: (a) Ours was a retrospective study based on chart reviews. Therefore, the reliability of the data may be less than that of the prospective studies. (b) We did not measure
